Authors

Latest:

Dr. Agnelli Discusses Apixaban for Venous Thromboembolism

Giancarlo Agnelli, MD, University of Perugia, Perugia, Italy, discusses the results of a study comparing the efficacy and safety of two doses of apixaban, an oral factor Xa inhibitor, with placebo for the treatment of venous thromboembolism.

Gilberto De Lima Lopes, MD

Latest:

Dr. Lopes on the Rationale to Stop Immunotherapy After 2 Years in Lung Cancer

Gilberto De Lima Lopes, MD, discusses the rationale to stop immunotherapy after 2 years in patients with lung cancer.

Gilberto Lopes Jr, MD

Latest:

Dr. Lopes Discusses Steroid Side Effects in Lung Cancer Management

Gilberto Lopes Jr, MD, a medical director for International Programs at Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, discusses steroid side effects in lung cancer management.

Gilberto Lopes, MD

Latest:

Final Thoughts on Effective Therapy and Financial Toxicity

Experts in cancer management share their final thoughts on effective treatment and individualized care vs financial toxicity.

Gilles A. Salles, MD, PhD

Latest:

Dr. Salles on Improving Immune Respone in Follicular Lymphoma

Gilles A. Salles, MD, PhD, Centre Hospitalier Lyon-Sud, discusses improving immune response in follicular lymphoma.

Gilles Salles MD, PhD

Latest:

Bispecific Antibodies May Revolutionize the Management of B-Cell Lymphoma

The safety profiles and the high response rates observed with bispecific antibodies in patients with B-cell lymphoma suggest that these agents possess the potential to revolutionize the management of these diseases, particularly follicular lymphoma.

Gina Battaglia

Latest:

CRC Tumor Sidedness Plays an Increasing Role in Clinical Practice

Prognosis, treatment outcomes, and molecular characteristics have become associated with sidedness in colorectal cancers making the distinction an essential characteristic for consideration in decison-making.

Gina Battaglia, PhD

Latest:

Emerging Uses for Circulating Tumor Cell Technology

Detection of circulating tumor cells, which are released from primary or metastatic lesions into the bloodstream and are the “seeds” for distant metastatic lesions, has been of interest in cancer research and treatment because these cells can potentially provide information on cancer detection, prognosis, and likelihood of treatment response with minimally invasive methods.

Gina Battalia, PhD

Latest:

Tailoring Therapy for HR-Positive Breast Cancer

Experts discuss the most effective ways to use new targeted therapies for patients with advanced hormone receptor-positive breast cancer in an OncLive Peer Exchange® panel.

Gina Columbus

Latest:

FDA Approval Sought for Frontline Cabozantinib/Nivolumab Combo in Advanced RCC

A supplemental new drug application has been submitted to the FDA for the combination of cabozantinib and nivolumab as a treatment for patients with advanced renal cell carcinoma.

Gina Z. D

Gina Z. D'Amato, MD

Latest:

Dr. D’Amato on Optimizing Treatment for Patients With Desmoid Tumors

Gina Z. D’Amato, MD, discusses optimizing treatment for patients with desmoid tumors.

Gina Z. D'Amato, MD, Sylvester Comprehensive Cancer Center

Ginny Vachon, PhD

Latest:

RECORD-3 Molecular Analysis Characterizes Poor-Risk Patients With mRCC

To best treat patients with clear cell renal cell carcinoma, incorporating precision biomarkers into the current nomogram is essential.

Giorgio Scagliotti, MD, PhD

Latest:

Dr. Scagliotti on the Phase III ASCEND-5 Study in ALK+ NSCLC

Giorgio Scagliotti, MD, PhD, professor of Medical Oncology, University of Torino, discusses the design and the results of the phase III ASCEND-5 study during an interview at the 2016 ESMO Congress.

Giorgio Scagliotti, MD, PhD, University of Turin

Giorgio V. Scagliotti, MD, PhD

Latest:

Dr. Giorgio Scagliotti on Taking a Targeted Approach to Immunotherapy in Lung Cancer

Giorgio Vittorio Scagliotti, MD, PhD

Latest:

Dr. Scagliotti on Preventive Measures to Reduce COVID-19 Risk in Oncology

Giorgio Vittorio Scagliotti, MD, PhD, discusses the precautionary measures implemented in clinical practice to protect patients with cancer from COVID-19.

Giovan Giuseppe Di Costanzo, MD

Latest:

Dr. Di Costanzo on the Effectiveness of Sorafenib in HCC

Giovan Giuseppe Di Costanzo, MD, Cardarelli Hospital, discusses a scoring system to predict the effectiveness of sorafenib (Nexavar) in hepatocellular carcinoma (HCC).

Giovanna Palatucci

Latest:

The Ratings Game

The rise of social networking websites that encourage patients to rate their physicians and discuss their experiences has some practitioners worried about the damage a malicious review could do to their practice.